top of page


Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline
Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.

nuaxia
6 hours ago2 min read


Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement
Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases.

nuaxia
1 day ago2 min read


FDA requires new NAION vision-loss risk warnings across GLP-1 receptor agonist medicines
The FDA has ordered class-wide labelling changes for GLP-1 receptor agonists following evidence of a potential association with rare but potentially permanent vision loss caused by non-arteritic anterior ischaemic optic neuropathy.

nuaxia
4 days ago2 min read


Lupin and Sandoz launch Ranluspec ranibizumab biosimilar across Europe following EC approval
Lupin and commercial partner Sandoz have begun launching Ranluspec, a ranibizumab biosimilar, across European markets excluding Germany, expanding commercial competition in treatments for retinal vascular diseases.

nuaxia
4 days ago2 min read


FDA approves STADA and Xbrane Lucamzi ranibizumab biosimilar for retinal diseases
The FDA has approved Lucamzi, a ranibizumab biosimilar developed by Xbrane Biopharma and commercialised through STADA, expanding treatment competition in retinal diseases.

nuaxia
Oct 302 min read


Alcon acquires Neurotech Pharmaceuticals for $550 million to expand retinal disease portfolio
Alcon is acquiring Neurotech Pharmaceuticals for a reported $550 million, adding Encelto and an encapsulated-cell therapy platform to its retinal disease portfolio.

nuaxia
Oct 222 min read


FDA approves Genentech Enspryng as first at-home subcutaneous treatment for thyroid eye disease
The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment option for adults with thyroid eye disease.

nuaxia
Oct 202 min read


FDA approves Viatris Ryzumvi eye drops for age-related presbyopia in adults
The FDA has approved Viatris' Ryzumvi eye drops for presbyopia in adults, expanding the product's use beyond reversal of pharmacologically induced pupil dilation.

nuaxia
Oct 192 min read


SpyGlass Pharma acquires Advanced Vision Science for $13m to secure intraocular lens manufacturing
SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house.

nuaxia
Oct 21 min read


Lupin licenses European rights to Tenpoint's YUVEZZI for presbyopia
The agreement expands Lupin's European ophthalmology portfolio by adding the first once-daily dual-agent eye drop approved for presbyopia while strengthening its specialty eye care strategy.

nuaxia
Aug 213 min read


Canadian Ophthalmologists Top C$1.18 Million in Gross Billings, Provincial Analysis Finds
New analysis of physician payment data places ophthalmology among Canada's highest-billing specialties, with median gross billings reaching C$1.18 million in British Columbia.

nuaxia
Aug 173 min read


Medscape Ophthalmologist Compensation Report 2026
The Medscape Ophthalmologist Compensation Report 2026 shows ophthalmology remains one of the highest-paying physician specialties

nuaxia
Jun 234 min read
bottom of page